Cargando…
Gene Therapy for Mucopolysaccharidosis Type II—A Review of the Current Possibilities
Mucopolysaccharidosis type II (MPS II) is a lysosomal storage disorder based on a mutation in the IDS gene that encodes iduronate 2-sulphatase. As a result, there is an accumulation of glycosaminoglycans—heparan sulphate and dermatan sulphate—in almost all body tissues, which leads to their dysfunct...
Autores principales: | Zapolnik, Paweł, Pyrkosz, Antoni |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197095/ https://www.ncbi.nlm.nih.gov/pubmed/34070997 http://dx.doi.org/10.3390/ijms22115490 |
Ejemplares similares
-
Nanoemulsions as Gene Delivery in Mucopolysaccharidosis Type I—A Mini-Review
por: Zapolnik, Paweł, et al.
Publicado: (2022) -
RNF6 as an Oncogene and Potential Therapeutic Target—A Review
por: Zapolnik, Paweł, et al.
Publicado: (2020) -
Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape
por: Rouse, Courtney J., et al.
Publicado: (2023) -
Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?
por: Horgan, Claire, et al.
Publicado: (2022) -
Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)